Navigation Links
Absolute Antibody Launches FleXpress™ High-Throughput Recombinant Antibody Production Service
Date:3/4/2020

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the launch of its FleXpress™ high-throughput recombinant antibody production service, which offers customers the flexibility to rapidly express a large number of antibodies at 80 ml scale. All production occurs in Absolute Antibody’s ISO-certified antibody manufacturing facility in Northeast England, which recently expanded to increase production capacity and meet the growing demand for recombinant antibody technology.

The high-throughput recombinant antibody production service is ideal for early-stage pharmaceutical researchers conducting pilot studies on a group of therapeutic antibody candidates, as well as reagent companies with a monoclonal antibody portfolio interested in converting their collection from hybridomas to recombinant production. Recombinant antibodies, long the standard in pharmaceutical development, are becoming increasingly popular for research and diagnostic applications due to their superior batch-to-batch reproducibility, antibody engineering options, and guaranteed long-term supply.

The antibody production service utilizes Absolute Antibody’s HEXpress™ antibody expression platform, a serum-free, mammalian transient expression system that offers a faster, more affordable alternative to stable CHO cell line generation. The proprietary system produces high-quality recombinant antibodies in any species, isotype or format, including multispecifics and fragments, with high purity and low endotoxin levels.

The FleXpress™ production line can recombinantly manufacture hundreds of different antibodies per week at 80 ml scale, allowing Absolute Antibody to quickly respond to customer needs for high-throughput small-to-medium-scale recombinant antibody production. It joins two other production lines at the company’s antibody manufacturing facility, which also offers the option to scale to multi-gram quantities in a matter of weeks.

“Absolute Antibody specializes in recombinant antibody technology, and we’ve developed a robust and reliable platform for high-throughput antibody production at relatively small scales,” said Catherine Bladen, PhD, Chief Operations Officer at Absolute Antibody. “Our new production line gives our customers the flexibility to rapidly and cost-effectively test recombinant versions of many different antibodies using our proven recombinant expression technology.”

In 2019, Absolute Antibody produced thousands of different recombinant antibodies, making 120 grams of protein in total, for customers across pharmaceuticals, biotechnology, research reagents, diagnostics, and academia. Since its founding in 2012, the company has also used its production platform to build a unique recombinant antibody catalog consisting of nearly 5,000 antibodies, all benefitting from antibody engineering technology. The FleXpress™ production service enables customers to utilize this same technology for their own recombinant antibody projects.

For more information, please visit our website here.

About Absolute Antibody, Ltd.
Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Visit absoluteantibody.com for more information.

Contact:
Lisa Merolla    
Director of Marketing
+1 617-377-4057 (extension 610)
l.merolla@absoluteantibody.com

Read the full story at https://www.prweb.com/releases/absolute_antibody_launches_flexpress_high_throughput_recombinant_antibody_production_service/prweb16944237.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Absolute Antibody Launches VivopureX™ Recombinant Antibodies for In Vivo Research
2. Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies
3. Schulman Associates IRB Acquires Absolute Research
4. Elusive quantum transformations found near absolute zero
5. Chan Zuckerberg Biohub Choose Geneious For Best Practice NGS Antibody Pipeline
6. Singh Biotechnology Receives Second FDA Orphan Drug Designation for its Novel Single Domain Antibody for the Treatment of Osteosarcoma by Targeting Intracellular STAT3
7. Thermo Fisher Scientific Addresses the Antibody Reproducibility Crisis with Panel Discussion
8. Merck uses Genedata Biologics to Scale-Up Bispecific Antibody Discovery Programs
9. GigaGen Announces Launch of New Antibody Discovery Service at 2017 BIO International Conference
10. Newest Port Company Revolutionizing Antibody Discovery Platforms
11. SCIEX Webinar to Explore Monoclonal Antibody Glycan Analysis up to 5 Times Faster Than HILIC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... March 30, 2020 , ... A joint venture between mobile ... earlier this year to bring telehealth to various government agencies, has now focused ... officials are currently?awaiting an Emergency Use Authorization (EUA) waiver from the FDA?to?perform?AI?testing in ...
(Date:4/1/2020)... ... March 31, 2020 , ... Bedoukian Research, Inc. ... a Joint Development Agreement that builds on each company’s expertise in developing efficient ... in the supply of high-quality insect pheromones as well as flavors and fragrances. ...
(Date:3/19/2020)... ... March 17, 2020 , ... ... collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to ... and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal ...
(Date:3/12/2020)... ... March 12, 2020 , ... With the beginning ... increases the business investment in Europe by inaugurating a new scientific facility for ... of the new Nanoscience Center Europe took place Tuesday, February 18, 2020, gathering ...
Breaking Biology Technology:
(Date:2/28/2020)... , ... February 28, 2020 , ... Meridian Clinical ... 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. Meridian is ... for the Best Clinical Trial Network award. These nominations were the result of two ...
(Date:2/28/2020)... ... February 27, 2020 , ... Regen Suppliers is now offering the top ... thread lift products are not only one of the only FDA Cleared options ... procedures are increasing exponentially in popularity, as they represent an excellent nonoperative method of ...
(Date:2/26/2020)... ... 25, 2020 , ... Renowned eye surgical practice led by Steven J. Dell, ... offer the FDA-approved, post-surgical, corrective Light Adjustable Lens (LAL) by RxSight™. Since offering this ... Dell Laser Consultants is also currently involved in the latest LAL FDA study. , ...
Breaking Biology News(10 mins):